Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

During a July episode of the Business of Biotech, Ebrahim Delpassand, M.D., founder, chairman, and CEO at RadioMedix, pointed out the importance of knowing, as a company, what you do best. It won’t be ...

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

The biopharma industry is rapidly evolving. As such, biopharma companies are facing a variety of operational challenges stemming from a high volume of siloed data coupled with regulatory scrutiny that ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

Vivani’s subdermal implant NanoPortal device, a platform drug delivery technology, is designed to deliver a near-constant and minimally fluctuating dose of an active pharmaceutical drug for a duration ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...